In silico studies on the interaction between bioactive ligands and ALK5, a biological target related to the cancer...

Area of Science:

• Medicinal Chemistry
• Computational Biology
• Oncology

Background:

• Transforming growth factor beta type I receptor (TGF-βRI or ALK5) is a significant biological target in cancer treatment.
• ALK5 inhibition presents a therapeutic strategy for various cancers, including breast, lung, and pancreatic cancers.

Purpose of the Study:

• To perform comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) studies on 70 ligands targeting ALK5.
• To develop and validate predictive computational models for ALK5 inhibitors.

Main Methods:

• Utilized CoMFA and CoMSIA quantitative structure-activity relationship (QSAR) methods.
• Validated the models using both internal (q(2)LOO) and external (r(2)test) cross-validation techniques.
• Analyzed CoMFA and CoMSIA maps to identify key physicochemical interactions.

Main Results:

• Achieved robust internal validation for both CoMFA (q(2)LOO = 0.887) and CoMSIA (q(2)LOO = 0.822) models.
• Demonstrated strong predictive power through external validation (CoMFA r(2)test = 0.998; CoMSIA r(2)test = 0.975).
• Identified critical physicochemical factors governing ligand-ALK5 interactions via generated maps.

Conclusions:

• The validated CoMFA and CoMSIA models provide reliable insights into ALK5 inhibitor design.
• Physicochemical evidence from the models guides molecular modifications for developing novel ALK5 inhibitors.
• This research supports the rational design of targeted cancer therapeutics.